Maravai LifeSciences Announces Pricing of an Upsized Initial Public Offering
November 19 2020 - 7:50PM
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a
global provider of life science reagents and services to
researchers and biotech innovators, today announced the pricing of
its upsized initial public offering of 60,000,000 shares of Class A
common stock at a public offering price of $27.00 per share, before
underwriting discounts and commissions, for gross proceeds of
$1,620,000,000. All shares of Class A common stock are being
offered by Maravai. The shares are expected to begin trading on the
Nasdaq Global Select Market on November 20, 2020, under the symbol
“MRVI.” The offering is expected to close on November 24, 2020,
subject to the satisfaction of customary closing conditions.
Additionally, Maravai has granted the underwriters a 30-day option
to purchase up to an additional 9,000,000 shares of Class A common
stock at the initial public offering price, less underwriting
discounts and commissions.
Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are
acting as joint book-running managers for the offering. BofA
Securities, Credit Suisse, UBS Investment Bank, Baird, William
Blair, Stifel and KeyBanc Capital Markets are also acting as joint
book-running managers, and Academy Securities, Loop Capital
Markets, Penserra Securities LLC and Tigress Financial Partners are
acting as co-managers for the offering.
Perella Weinberg Partners L.P. served as capital markets advisor
to Maravai. Kirkland & Ellis LLP provided legal counsel to
Maravai and Davis Polk & Wardwell LLP provided legal counsel to
the underwriters.
A registration statement on Form S-1 relating to these
securities has been filed with the U.S. Securities and Exchange
Commission and became effective on November 19, 2020. The offering
is being made only by means of a prospectus. Copies of the final
prospectus, when available, may be obtained from: Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014, or by email at
prospectus@morganstanley.com; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at 877-821-7388 or by email at
Prospectus_Department@Jefferies.com; or Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street, New
York, NY 10282, by telephone at 866-471-2526, by
facsimile at 212-902-9316 or
by email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About MaravaiMaravai is a leading life sciences
company providing critical products to enable the development of
drug therapies, diagnostics, novel vaccines and support research on
human diseases through its portfolio of companies and their
proprietary capabilities and products. Maravai’s companies are
leaders in providing products and services in the fields of nucleic
acid synthesis, bioprocess impurity detection and analysis, and
protein labeling and detection to many of the world's leading
biopharmaceutical, vaccine, diagnostics, and cell and gene therapy
companies.
Contact
Sara Michelmore
+1 781-235-3060
maravai@macbiocom.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Sep 2023 to Sep 2024